下呼吸道铜绿假单胞菌的多耐药现状及临床策略  

作　　者：李鸿雁[1] 夏前明[1] 李福祥[1] 全燕[1] 朱忠立[1] 

机构地区：[1]四川成都军区总医院呼吸科,610083

出　　处：《临床医药实践》2010年第1X期7-8,41,共3页Proceeding of Clinical Medicine

摘　　要：目的:了解近几年医院铜绿假单胞菌(Pseu-domonas AERUGINOSA,PA)在慢性肺部疾病中的多耐药状况和病种分布,以指导合理用药。方法:收集医院呼吸科2004年1月～2007年12月分离的耐药PA,采用K-B法做药敏试验,用PEMS3.1软件包分析。结果:呼吸道1176株耐药PA中多耐药株占有率逐年升高,主要分布于慢性阻塞性肺病、呼吸机相关肺炎及支扩病人。PA对亚胺培南、哌拉西林/他唑巴坦、头孢吡肟、阿米卡星的耐药率相对较低。结论:PA在慢性肺部疾病中的多耐药性已十分突出,应引起临床医生的重视;应着重预防,合理用药,加强监测和隔离;治疗应选择科学的联合用药方案。Objective:To understand the hospital in recen years,Pseudomonas AERUGINOSA(Pseudomonas AERUGINOSA,PA) in chronic lung disease in the multi-drug resistance status and distribution of diseases in order to guide rational drug use.Methods:Respiratory Hospital,January 2004-December 2007 separation of drug-resistant PA,using KB method to do the sensitivity test,using PEMS 3.1 package analysis.Results:of respira-tory tract 1176 in the multi-drug-resistant strains of drug-resistan PA share increased year by year,mainly in patients with chronic obstructive pulmonary disease,ventilator-associated pneumonia and patients with branch expansion.PA to IMIPENEM,PIPERACILLIN / TAZOBACTAM,CEFEPIME,AMIKACIN resistance was relatively low.Conclusion:PA in patients with chronic lung disease in the multi-drug resistance has been very prominent should arouse the clinician's attention;should focus on prevention rational use of medicines,and strengthen monitoring and isolation;treatment of combination therapy should be selected science programs.

关 键 词：铜绿假单胞菌 耐药性 感染 抗菌药物 

分 类 号：R446.5[医药卫生—诊断学] R56[医药卫生—临床医学]